Skip to content
DataLookout
Menu

NCT07907640

Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in NT-proBNP
Timeframe: Baseline (Month 0) to Month 12

Secondary (10)

Change in LVEF
Change in serum creatinine
Change in eGFR
Change in serum potassium
Change in KCCQ overall summary score
Show 5 moreShow less
Cardiovascular death or first heart failure hospitalisation (composite)
Adverse events and serious adverse events
Adverse events of special interest
Change in Dietary Diversity Score (DDS)
Association between DDS and clinical outcomes

Arms and interventions

Savagen (sacubitril/valsartan)

Patients with HFrEF starting Savagen as part of routine care. Initiation and titration by the treating physician per standard institutional protocol; visits at Month 0, 6 and 12.

Drugs: Savagen (sacubitril/valsartan)

Sites

2 sites in 1 country